Allakos Inc. (ALLK)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
ALLK Chart
Why Is Allakos Stock Plunging On Monday?
On Monday, Allakos Inc (NASDAQ: ALLK) revealed topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU), a skin disorder.
All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy
Allakos (ALLK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Allakos Runs Up Into A Near-Term Catalyst
Allakos shifted focus to AK006 in 2024 after lirentelimab's failure in phase 2 trials for atopic dermatitis and chronic spontaneous urticaria. Phase 1 work with intravenous and subcutaneous AK006 demonstrates that the drug may not require frequent dosing, which may be important given potential competition from oral remibrutinib. Upcoming Q1'25 data from a randomized, double-blind, placebo-controlled trial of IV AK006 in over 30 CSU patients is a near-term catalyst.
Allakos Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| LR Larry Randall Alta Partners Management Company LP | 2.55M | $3.08M | $3.08M | -$0.25 | - |
Allakos Inc. (ALLK) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Allakos Inc. Profile
| - Industry | - Sector | Robert Alexander CEO | NASDAQ (NGS) Exchange | 01671P100 CUSIP |
| US Country | 131 Employees | - Last Dividend | - Last Split | 19 Jul 2018 IPO Date |
Overview
Allakos Inc. is a pioneering clinical-stage biotechnology company based in the United States, specifically headquartered in San Carlos, California. Founded in the year 2012, the company has dedicated itself to the development of innovative therapeutics. Its main focus lies in targeting immunomodulatory receptors that are present on immune effector cells, which play crucial roles in allergy, inflammatory, and proliferative diseases. Through its groundbreaking research and development, Allakos Inc. endeavors to bring new and effective treatment options to patients suffering from these conditions, contributing significantly to the field of biotechnology and medical science.
Products and Services
Allakos Inc. is at the forefront of developing advanced therapeutic solutions, with its prime focus on the lead product candidate:
- AK006 - This is the company's flagship product candidate currently undergoing Phase I clinical trials. AK006 is designed to selectively target critical immunomodulatory receptors on immune effector cells. Its primary indication is for the treatment of chronic spontaneous urticaria (CSU), a condition characterized by the spontaneous appearance of wheals (hives), angioedema, or both, for more than six weeks without an apparent cause. In addition, Allakos is exploring potential applications of AK006 in treating other related indications. The development of AK006 epitomizes Allakos Inc.'s commitment to addressing unmet medical needs in allergy, inflammatory, and proliferative diseases through innovative biotechnological approaches.
